Hepatitis C virus elimination programs report encouraging results: Is elimination within reach?

April 13, 2018, European Association for the Study of the Liver

Two nationwide programmes in Georgia and Iceland, which were designed to eliminate hepatitis C virus (HCV) at the population level, have reported encouraging results, suggesting that these countries could be on target to achieve their elimination goals. Although both programmes have adopted slightly different approaches, both have reported high levels of engagement, initiation of direct-acting antiviral agents (DAAs), and cure among patients chronically infected with HCV.

Worldwide, 71 million people are estimated to have chronic hepatitis C , resulting in an estimated 700,000 deaths per year from hepatocellular carcinoma or cirrhosis. The availability of oral, well-tolerated DAAs that can achieve cure rates of over 95% has led to the development of World Health Organization (WHO) elimination targets that propose a 90% reduction in HCV incidence and a 65% reduction in HCV-related mortality by 2030.

Georgia programme: latest data

The world's first hepatitis C elimination programme was initiated in Georgia in collaboration with the US Centers for Disease Control and Prevention (CDC), and with a commitment from Gilead Sciences to donate DAAs.15 The programme was initiated in April 2015, and the results from its first 2 years in action were presented today at The International Liver Congress 2018 in Paris, France.

"In Georgia, we have set out to achieve 90-95-95 targets by 2020, which means that we want to diagnose 90% of all HCV-infected individuals, we want to treat 95% of those diagnosed, and we want to cure 95% of those treated," explained Professor Tengiz Tsertsvadze from the Infectious Diseases, AIDS and Clinical Immunology Research Center in Tbilisi, Georgia. "We had previously estimated that there were around 150,000 adults with HCV infection living in Georgia, which represents a prevalence in our population of 5.4%".

Hepatitis C screening programmes began in Georgia in 2015 and, by the end of April 2017, 43,989 individuals (29.3% of the estimated total population) had been diagnosed with HCV infection and registered with the elimination programme. A total of 33,673 individuals had initiated treatment with DAAs, and 24,273 individuals had achieved a sustained virological response (SVR), i.e. were cured.

"In the first 2 years of this programme, we have diagnosed more than one-quarter of our HCV-infected adults in Georgia, we have treated 77% of those diagnosed, and cured over 95% of those completing treatment," said Prof. Tsertsvadze. "Our priorities now are to develop innovative strategies to increase awareness, expand access to high-quality screening, and remove diagnostic and treatment barriers."

Iceland programme: first results

The Treatment as Prevention for Hepatitis C (TraP HepC) programme was initiated in Iceland in January 2016 with the aim of eliminating chronic HCV infection as a public health threat in Iceland.17 The programme prioritizes treatment for people who inject drugs (PWID), patients with advanced liver disease, and prisoners, and treats patients who relapse or become reinfected promptly.17 The study presented today assessed the impact of the TraP HepC programme on the prevalence of active HCV infection among PWID admitted to the Society of Alcoholism and other Addictions' (SÁÁ´s) Vogur Hospital, Iceland's largest addiction treatment centre, where more than 90% of PWID in the country are treated. During the first 15 months of the programme, 554 individuals with HCV infection were evaluated and DAAs were initiated in 518 individuals, with 473 (91.3%) completing treatment and 96% of these remaining HCV RNA negative at 12 weeks post-treatment, therefore cured of HCV infection. The prevalence of active HCV infection (viraemia) among PWID at Vogur Hospital showed a dramatic 72% reduction, from 43% in 2015, prior to initiation of the TraP HepC programme, to 12% in 2017.

"Encouragingly, even in individuals with recent intravenous drug use, DAA treatment, although challenging, resulted in an 87% cure rate, including in those that did not complete the treatment regimen," said Dr. Valgerdur Rúnarsdóttir from Vogur Hospital in Reykjavík, Iceland. "People who inject drugs are key drivers of HCV infection in Iceland and this population should be a focus of treatment scale-up. We would like to emphasize and encourage collaboration between addiction centres in both screening and treating HCV. This is key to success in reaching the population in focus."

"There is no doubt that this is a challenging programme, but we believe it has been initiated successfully in Iceland and that we are well placed to achieve our elimination goal."18

"These two HCV elimination programmes in two different settings show promising results," said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. "However, the programme in Iceland is unique and special because it is a defined (or better delimited) situation on an island with a defined target population. If elimination of HCV is possible without a vaccine, it will surely be possible in Iceland. The programme in Georgia still has a long way to go, as three quarters of patients are not yet diagnosed."

Explore further: Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

Related Stories

Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

April 12, 2018
A prospective, longitudinal study involving more than 1,000 people who inject drugs has identified a promising role for linkage to care specialists in facilitating rapid access to hepatitis C treatment. The study, which was ...

Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure

April 12, 2018
A large-scale study evaluating the feasibility of decentralized care and the provision of free direct-acting antiviral agents (DAAs) has reported high rates of cure among a population of almost 20,000 individuals completing ...

Scotland: Direct-acting antiviral agent therapy reduces the burden of HCV-related decompensated cirrhosis

April 12, 2018
Two presentations given this week at The International Liver Congress 2018 in Paris, France illustrate the impact that DAAs can have in averting HCV-related liver disease, and reducing the clinical and economic burden of ...

Only nine countries on track to eliminate hepatitis C

November 1, 2017
New data on hepatitis C released by the Polaris Observatory, and presented today at the World Hepatitis Summit (WHS) in Sao Paulo, Brazil shows that nine countries—Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, ...

UN's health body urges Hepatitis C offensive

April 13, 2018
Hepatitis C is easily cured. Yet, about 400,000 people die of the liver disease every year as only a smattering get the medicine they need.

First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection

April 12, 2018
The results of the first real-world studies assessing the effectiveness and safety of glecaprevir/pibrentasvir (G/P) in patients with chronic hepatitis C virus (HCV) infection have confirmed high rates of viral suppression ...

Recommended for you

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Researchers discover new interactions between Ebola virus and human proteins

December 13, 2018
Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ...

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.